Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 3, 2014, Pages

  Brantley, S J ^a   Gufford, B T ^b   Dua, R ^a   Fediuk, D J ^a   Graf, T N ^c   Scarlett, Y V ^d   Frederick, K S ^e   Fisher, M B ^f   Oberlies, N H ^c   Paine, M F ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f ProPharma Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A; MIDAZOLAM; SILIBININ; SILYMARIN; WARFARIN;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG HALF LIFE; DRUG MEGADOSE; ENANTIOMER; ENZYME INHIBITION; GENOTYPE; HERB DRUG INTERACTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SILYBUM MARIANUM; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84902505301     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.69     Document Type: Article

References (48)

1. Gurley, B.J. Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta Med. 78, 1478-1489 (2012).
2. Hermann, R. & von Richter, O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 78, 1458-1477 (2012).
3. de Lima Toccafondo Vieira, M. & Huang, S.M. Botanical-drug interactions: a scientific perspective. Planta Med. 78, 1400-1415 (2012).
4. Paine, M.F. & Oberlies, N.H. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin. Drug Metab. Toxicol. 3, 67-80 (2007). (Pubitemid 47307455)
5. European Medicines Agency. Guideline on the Investigation of Drug Interactions (2012). http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2012/07/WC500129606.pdf Accessed 2 August 2012.
6. Food and Drug Administration. Draft Guidance: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (2012). http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf Accessed 2 August 2012.
7. Fahmi, O.A. et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab. Dispos. 37, 1658-1666 (2009).
8. Huang, S.M. & Rowland, M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther. 91, 542-549 (2012).
9. Blumenthal, M., Lindstrom, A., Lynch, M. & Rea, P. Market Report. Herb sales continue growth - up 3.3% in 2010. HerbalGram 90, 64-67 (2011).
10. Kroll, D.J., Shaw, H.S. & Oberlies, N.H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther. 6, 110-119 (2007). (Pubitemid 46871844)
11. Graf, T.N., Wani, M.C., Agarwal, R., Kroll, D.J. & Oberlies, N.H. Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med. 73, 1495-1501 (2007). (Pubitemid 350240510)
12. Monti, D. et al. Enzymatic kinetic resolution of silybin diastereoisomers. J. Nat. Prod. 73, 613-619 (2010).
13. Zuber, R. et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res. 16, 632-638 (2002). (Pubitemid 35334183)
14. Sridar, C., Goosen, T.C., Kent, U.M., Williams, J.A. & Hollenberg, P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos. 32, 587-594 (2004). (Pubitemid 38668150)
15. Brantley, S.J., Oberlies, N.H., Kroll, D.J. & Paine, M.F. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J. Pharmacol. Exp. Ther. 332, 1081-1087 (2010).
16. Brantley, S.J., Graf, T.N., Oberlies, N.H. & Paine, M.F. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab. Dispos. 41, 1662-1670 (2013).
17. Gurley, B.J. et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther. 76, 428-440 (2004). (Pubitemid 39469867)
18. Gurley, B. et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 46, 201-213 (2006).
19. Han, Y., Guo, D., Chen, Y., Chen, Y., Tan, Z.R. & Zhou, H.H. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur. J. Clin. Pharmacol. 65, 585-591 (2009).
20. Ngo, N. et al. The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation. J. Exp. Pharmacol. 2010, 83-91 (2010).
21. Ngo, N. et al. Identification of a cranberry juice product that inhibits enteric CYP3Amediated first-pass metabolism in humans. Drug Metab. Dispos. 37, 514-522 (2009).
22. Wen, Z., Dumas, T.E., Schrieber, S.J., Hawke, R.L., Fried, M.W. & Smith, P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab. Dispos. 36, 65-72 (2008).
23. Doehmer, J., Weiss, G., McGregor, G.P. & Appel, K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol. In Vitro 25, 21-27 (2011).
24. Lo, M.W., Goldberg, M.R., McCrea, J.B., Lu, H., Furtek, C.I. & Bjornsson, T.D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 58, 641-649 (1995). (Pubitemid 26018849)
25. Hanley, M.J., Masse, G., Harmatz, J.S., Court, M.H.&Greenblatt, D.J. Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. Clin. Pharmacol. Ther. 92, 651-657 (2012).
26. Hawke, R.L. et al.; SyNCH Trial Group. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J. Clin. Pharmacol. 50, 434-449 (2010).
27. Lin, X.Z. et al. Liver volume in patients with or without chronic liver diseases. Hepatogastroenterology. 45, 1069-1074 (1998).
28. Nakai, K. et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab. Dispos. 36, 1786-1793 (2008).
29. Johnson, T.N., Boussery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189-206 (2010).
30. Björkman, S., Wada, D.R., Berling, B.M. & Benoni, G. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J. Pharm. Sci. 90, 1226-1241 (2001).
31. Boecker, B.B. Reference values for basic human anatomical and physiological characteristics for use in radiation protection. Radiat. Prot. Dosimetry 105, 571-574 (2003). (Pubitemid 37161291)
32. Luecke, R.H., Wosilait, W.D., Pearce, B.A. & Young, J.F. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49, 90-103 (1994).
33. Chan, E., McLachlan, A.J., Pegg, M., MacKay, A.D., Cole, R.B. & Rowland, M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with racwarfarin. Br. J. Clin. Pharmacol. 37, 563-569 (1994). (Pubitemid 24197150)
34. Kunze, K.L., Eddy, A.C., Gibaldi, M. & Trager, W.F. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by ®-warfarin. Chirality 3, 24-29 (1991).
35. Langlois, S., Kreeft, J.H., Chouinard, G., Ross-Chouinard, A., East, S. & Ogilvie, R.I. Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. Br. J. Clin. Pharmacol. 23, 273-278 (1987). (Pubitemid 17108187)
36. Barter, Z.E. et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8, 33-45 (2007). (Pubitemid 46043890)
37. Obach, R.S. Predicting clearance in humans from in vitro data. Curr. Top. Med. Chem. 11, 334-339 (2011).
38. Poulin, P., Schoenlein, K. & Theil, F.P. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J. Pharm. Sci. 90, 436-447 (2001).
39. Deng, J.W. et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm. Res. 25, 1807-1814 (2008).
40. Loizou, G. & Hogg, A. MEGen: A Physiologically Based Pharmacokinetic Model Generator. Front. Pharmacol. 2, 56 (2011).
41. Kim, N.C., Graf, T.N., Sparacino, C.M., Wani, M.C. & Wall, M.E. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org. Biomol. Chem. 1, 1684-1689 (2003).
42. Davis-Searles, P.R. et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 65, 4448-4457 (2005). (Pubitemid 40775685)
43. Ma, J.D. et al. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J. Clin. Pharmacol. 44, 570-576 (2004).
44. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation (2001). www.fda.gov/Drugs/Guidance Compliance Regulatory Information/Guidances/ucm064964.htm Accessed 2 August 2012.
45. Sullivan-Klose, T.H. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996). (Pubitemid 26288624)
46. Kashuba, A.D., Bertino, J.S. Jr, Rocci, M.L. Jr, Kulawy, R.W., Beck, D.J. & Nafziger, A.N. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin. Pharmacol. Ther. 64, 269-277 (1998). (Pubitemid 28462287)
47. Kharasch, E.D., Jubert, C., Senn, T., Bowdle, T.A. & Thummel, K.E. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J. Clin. Pharmacol. 39, 664-669 (1999).
48. Yacobi, A. et al. Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. J. Clin. Pharmacol. 40, 826-835 (2000).